|
February 9, 2010
|
| 09:00 EDT |  | BMRN |
| theflyonthewall.com: | On The Fly: Analysts Upgrade Summary | | MOST NOTEWORTHY: Prosperity Bancshares (PRSP), Fortinet (FTNT) and Lamart Advertising (LAMR) were today's noteworthy upgrades: B. Riley upgraded Prosperity Bancshares to Buy from Neutral after the company acquired 19 Texas branches of Missouri-based First Bank. The firm has a $45 price target on shares. JP Morgan upgraded Fortinet to Overweight from Neutral on valuation following the recent pullback in shares. The firm has a $20 price target on the stock. Wells Fargo upgraded Lamar Advertising to Outperform from Market Perform. The firm believes the stock's risk/reward ratio is compelling, as its checks indicate that advertising continues to accelerate in Q1...OTHER UPGRADES: Caterpillar (CAT) was upgraded to Overweight from Underweight at Morgan Stanley. SAP AG (SAP) was upgraded to Market Perform from Underperform at FBR Capital. BioMarin (BMRN) was raised to Buy from Hold at Roth Capital. :theflyonthewall.com |
|
| 06:27 EDT |  | BMRN |
|
|
February 8, 2010
|
| 08:38 EDT |  | BMRN |
| theflyonthewall.com: | BioMarin downgraded to Hold from Buy at Brean Murray | | :theflyonthewall.com |
|
|
February 5, 2010
|
| 11:57 EDT |  | BMRN |
|
|
February 4, 2010
|
| 16:40 EDT |  | BMRN |
| theflyonthewall.com: | BioMarin provides update on the Phase I/II trial for BMN 110 | | BioMarin Pharmaceutical announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA, or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010. Key Observations: Keratan sulfate (KS) levels fall within a few weeks after the start of therapy. Improvements in 6-minute walk distance and 3-minute stair climb at 24 weeks are consistent with those observed with clinical studies for MPS I, MPS II, and MPS VI. The frequency and severity of infusion reactions appear comparable to those observed with Naglagyme and Aldurazyme. :theflyonthewall.com |
|
| 16:28 EDT | | BMRN |
|
| 16:27 EDT |  | BMRN |
| theflyonthewall.com: | BioMarin sees FY10 revenue $374M-$405M vs. consensus of $398.27M | | :theflyonthewall.com |
|
| 16:06 EDT | | BMRN |
|
|
February 1, 2010
|
| 07:54 EDT |  | BMRN |
| theflyonthewall.com: | BioMarin target raised to $23 from $20 at Jefferies | | Jefferies believes BioMarin's GALNS and PEG-PAL programs are not being fully reflected in the stock's valuation. The firm raised its target on shares and reiterates a Buy rating on the stock. :theflyonthewall.com |
|
Subscribe for More Information